Global Glucose Dependent Insulinotropic Receptor 麻豆原创 Research Report 2023

Publication ID:

PB503240209

Publication Date:

March 23, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Glucose Dependent Insulinotropic Receptor market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Glucose Dependent Insulinotropic Receptor is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Glucose Dependent Insulinotropic Receptor in Type 2 Diabetes is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Glucose Dependent Insulinotropic Receptor include Amgen Inc, Arena Pharmaceuticals Inc, CymaBay Therapeutics Inc, Dong-A Socio Holdings Co Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hyundai Pharmaceutical Co Ltd, Kowa Co Ltd and Merck & Co Inc, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glucose Dependent Insulinotropic Receptor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glucose Dependent Insulinotropic Receptor.
The Glucose Dependent Insulinotropic Receptor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Glucose Dependent Insulinotropic Receptor market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glucose Dependent Insulinotropic Receptor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Amgen Inc
Arena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Dong-A Socio Holdings Co Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Hyundai Pharmaceutical Co Ltd
Kowa Co Ltd
Merck & Co Inc
Novartis AG
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Yuhan Corp
Segment by Type
DA-1241
GSK-2041706
HD-0471042
HD-0471953
HOB-047
MBX-2982
Others
Segment by Application
Type 2 Diabetes
Obesity
Chronic Obstructive Pulmonary Disease (COPD)
Dyslipidemia
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glucose Dependent Insulinotropic Receptor companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Glucose Dependent Insulinotropic Receptor 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 DA-1241
1.2.3 GSK-2041706
1.2.4 HD-0471042
1.2.5 HD-0471953
1.2.6 HOB-047
1.2.7 MBX-2982
1.2.8 Others
1.3 麻豆原创 by Application
1.3.1 Global Glucose Dependent Insulinotropic Receptor 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Type 2 Diabetes
1.3.3 Obesity
1.3.4 Chronic Obstructive Pulmonary Disease (COPD)
1.3.5 Dyslipidemia
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Glucose Dependent Insulinotropic Receptor 麻豆原创 Perspective (2018-2029)
2.2 Glucose Dependent Insulinotropic Receptor Growth Trends by Region
2.2.1 Global Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Glucose Dependent Insulinotropic Receptor Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Glucose Dependent Insulinotropic Receptor Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Glucose Dependent Insulinotropic Receptor 麻豆原创 Dynamics
2.3.1 Glucose Dependent Insulinotropic Receptor Industry Trends
2.3.2 Glucose Dependent Insulinotropic Receptor 麻豆原创 Drivers
2.3.3 Glucose Dependent Insulinotropic Receptor 麻豆原创 Challenges
2.3.4 Glucose Dependent Insulinotropic Receptor 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Glucose Dependent Insulinotropic Receptor Players by Revenue
3.1.1 Global Top Glucose Dependent Insulinotropic Receptor Players by Revenue (2018-2023)
3.1.2 Global Glucose Dependent Insulinotropic Receptor Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Glucose Dependent Insulinotropic Receptor 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Glucose Dependent Insulinotropic Receptor Revenue
3.4 Global Glucose Dependent Insulinotropic Receptor 麻豆原创 Concentration Ratio
3.4.1 Global Glucose Dependent Insulinotropic Receptor 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glucose Dependent Insulinotropic Receptor Revenue in 2022
3.5 Glucose Dependent Insulinotropic Receptor Key Players Head office and Area Served
3.6 Key Players Glucose Dependent Insulinotropic Receptor Product Solution and Service
3.7 Date of Enter into Glucose Dependent Insulinotropic Receptor 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Glucose Dependent Insulinotropic Receptor Breakdown Data by Type
4.1 Global Glucose Dependent Insulinotropic Receptor Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Glucose Dependent Insulinotropic Receptor Forecasted 麻豆原创 Size by Type (2024-2029)
5 Glucose Dependent Insulinotropic Receptor Breakdown Data by Application
5.1 Global Glucose Dependent Insulinotropic Receptor Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Glucose Dependent Insulinotropic Receptor Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Glucose Dependent Insulinotropic Receptor 麻豆原创 Size (2018-2029)
6.2 North America Glucose Dependent Insulinotropic Receptor 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Country (2018-2023)
6.4 North America Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Glucose Dependent Insulinotropic Receptor 麻豆原创 Size (2018-2029)
7.2 Europe Glucose Dependent Insulinotropic Receptor 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Country (2018-2023)
7.4 Europe Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Glucose Dependent Insulinotropic Receptor 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Glucose Dependent Insulinotropic Receptor 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Glucose Dependent Insulinotropic Receptor 麻豆原创 Size (2018-2029)
9.2 Latin America Glucose Dependent Insulinotropic Receptor 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Glucose Dependent Insulinotropic Receptor 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Glucose Dependent Insulinotropic Receptor 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Glucose Dependent Insulinotropic Receptor 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen Inc
11.1.1 Amgen Inc Company Detail
11.1.2 Amgen Inc Business Overview
11.1.3 Amgen Inc Glucose Dependent Insulinotropic Receptor Introduction
11.1.4 Amgen Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.1.5 Amgen Inc Recent Development
11.2 Arena Pharmaceuticals Inc
11.2.1 Arena Pharmaceuticals Inc Company Detail
11.2.2 Arena Pharmaceuticals Inc Business Overview
11.2.3 Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Introduction
11.2.4 Arena Pharmaceuticals Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.2.5 Arena Pharmaceuticals Inc Recent Development
11.3 CymaBay Therapeutics Inc
11.3.1 CymaBay Therapeutics Inc Company Detail
11.3.2 CymaBay Therapeutics Inc Business Overview
11.3.3 CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Introduction
11.3.4 CymaBay Therapeutics Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.3.5 CymaBay Therapeutics Inc Recent Development
11.4 Dong-A Socio Holdings Co Ltd
11.4.1 Dong-A Socio Holdings Co Ltd Company Detail
11.4.2 Dong-A Socio Holdings Co Ltd Business Overview
11.4.3 Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Introduction
11.4.4 Dong-A Socio Holdings Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.4.5 Dong-A Socio Holdings Co Ltd Recent Development
11.5 F. Hoffmann-La Roche Ltd
11.5.1 F. Hoffmann-La Roche Ltd Company Detail
11.5.2 F. Hoffmann-La Roche Ltd Business Overview
11.5.3 F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Introduction
11.5.4 F. Hoffmann-La Roche Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.5.5 F. Hoffmann-La Roche Ltd Recent Development
11.6 GlaxoSmithKline Plc
11.6.1 GlaxoSmithKline Plc Company Detail
11.6.2 GlaxoSmithKline Plc Business Overview
11.6.3 GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Introduction
11.6.4 GlaxoSmithKline Plc Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.6.5 GlaxoSmithKline Plc Recent Development
11.7 Hyundai Pharmaceutical Co Ltd
11.7.1 Hyundai Pharmaceutical Co Ltd Company Detail
11.7.2 Hyundai Pharmaceutical Co Ltd Business Overview
11.7.3 Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Introduction
11.7.4 Hyundai Pharmaceutical Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.7.5 Hyundai Pharmaceutical Co Ltd Recent Development
11.8 Kowa Co Ltd
11.8.1 Kowa Co Ltd Company Detail
11.8.2 Kowa Co Ltd Business Overview
11.8.3 Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Introduction
11.8.4 Kowa Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.8.5 Kowa Co Ltd Recent Development
11.9 Merck & Co Inc
11.9.1 Merck & Co Inc Company Detail
11.9.2 Merck & Co Inc Business Overview
11.9.3 Merck & Co Inc Glucose Dependent Insulinotropic Receptor Introduction
11.9.4 Merck & Co Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.9.5 Merck & Co Inc Recent Development
11.10 Novartis AG
11.10.1 Novartis AG Company Detail
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG Glucose Dependent Insulinotropic Receptor Introduction
11.10.4 Novartis AG Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.10.5 Novartis AG Recent Development
11.11 Taisho Pharmaceutical Holdings Co Ltd
11.11.1 Taisho Pharmaceutical Holdings Co Ltd Company Detail
11.11.2 Taisho Pharmaceutical Holdings Co Ltd Business Overview
11.11.3 Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Introduction
11.11.4 Taisho Pharmaceutical Holdings Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.11.5 Taisho Pharmaceutical Holdings Co Ltd Recent Development
11.12 Takeda Pharmaceutical Co Ltd
11.12.1 Takeda Pharmaceutical Co Ltd Company Detail
11.12.2 Takeda Pharmaceutical Co Ltd Business Overview
11.12.3 Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Introduction
11.12.4 Takeda Pharmaceutical Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.12.5 Takeda Pharmaceutical Co Ltd Recent Development
11.13 Yuhan Corp
11.13.1 Yuhan Corp Company Detail
11.13.2 Yuhan Corp Business Overview
11.13.3 Yuhan Corp Glucose Dependent Insulinotropic Receptor Introduction
11.13.4 Yuhan Corp Revenue in Glucose Dependent Insulinotropic Receptor Business (2018-2023)
11.13.5 Yuhan Corp Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Amgen Inc
Arena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Dong-A Socio Holdings Co Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Hyundai Pharmaceutical Co Ltd
Kowa Co Ltd
Merck & Co Inc
Novartis AG
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Yuhan Corp

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.